Chimerix (NASDAQ:CMRX) Cut to “Sell” at StockNews.com

Chimerix (NASDAQ:CMRX) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.

Several other equities research analysts also recently issued reports on CMRX. Wedbush reiterated an “outperform” rating and set a $6.00 price target on shares of Chimerix in a report on Monday, February 12th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Chimerix in a report on Friday, March 1st.

Chimerix Price Performance

Shares of NASDAQ CMRX opened at $0.96 on Tuesday. The business has a 50-day moving average of $0.98 and a 200-day moving average of $1.00. Chimerix has a fifty-two week low of $0.88 and a fifty-two week high of $1.57. The stock has a market capitalization of $86.31 million, a price-to-earnings ratio of -1.04 and a beta of 1.13.

Chimerix (NASDAQ:CMRX) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Chimerix had a negative return on equity of 41.32% and a negative net margin of 25,337.96%. During the same quarter last year, the company earned ($0.24) EPS. On average, sell-side analysts expect that Chimerix will post -0.85 EPS for the current year.

Institutional Trading of Chimerix

A number of institutional investors have recently bought and sold shares of the business. RA Capital Management L.P. bought a new position in Chimerix in the third quarter valued at approximately $6,240,000. Acadian Asset Management LLC increased its stake in shares of Chimerix by 15.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock valued at $2,304,000 after purchasing an additional 291,981 shares during the last quarter. Vestal Point Capital LP acquired a new position in shares of Chimerix during the 4th quarter worth $1,348,000. Bank of New York Mellon Corp lifted its position in shares of Chimerix by 190.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company’s stock worth $568,000 after buying an additional 387,638 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in shares of Chimerix by 17.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 499,391 shares of the biopharmaceutical company’s stock worth $481,000 after buying an additional 72,719 shares during the last quarter. Institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.